RNA干扰对慢性粒细胞白血病bcr/abl融合基因表达的抑制作用  

Inhibitory effect of RNA interference on chronic myeloid leukemia bcr/abl oncogene expression

作　　者：马晓霞[1] 王椿[1] 卫菊[1] 秦尤文[1] 颜式可[1] 高彦荣[1] 蔡琦[1] 

机构地区：[1]上海市第一人民医院血液科,200080

出　　处：《中华血液学杂志》2005年第6期359-362,共4页Chinese Journal of Hematology

摘　　要：目的研究RNA干扰(RNAi)效应对慢性粒细胞白血病(CML)bcr/abl融合基因表达的抑制作用。方法体外化学合成针对bcr/abl融合基因的小干扰RNA(siRNA),并用电穿孔方法将siRNA转染K562细胞株,以未转染的细胞及非特异性的siRNA转染细胞作对照;同时转染带有增强型绿色荧光蛋白(EGFP)的载体作为阳性对照,流式细胞术检测其绿色荧光以确定转染效率;实时定量RTPCR及Westernblot法检测siRNA的抑制效应。MTT法检测细胞增殖抑制率。膜联蛋白Ⅴ(AnnexinⅤ)及碘化丙锭双染法测细胞凋亡率。结果电穿孔的转染效率可达70%;化学合成的siRNA可以抑制bcr/abl融合基因在mRNA和蛋白水平的表达;特异性siRNA可以抑制细胞增殖,转染24h细胞增殖抑制率达47%,48h达56%;特异性siRNA转染细胞24h组凋亡率为15.05%,48h组为19.47%,与对照组(1.00%)比较明显提高。结论在细胞水平上,化学合成的siRNA可以抑制bcr/abl融合基因的表达,为利用RNA干扰作为基因治疗的研究奠定基础。Objective To investigate the inhibitory effect of RNA interference on chronic myeloid leukemia (CML) bcr/abl oncogene expression. Methods The small interference RNAs(siRNAs) were synthesized in vitro. K562 cells stably expressing bcr/abl gene were transfected with the siRNA by electroporation, both the non-transfected cells and non-specific siRNAs transfected cells were taken as controls. The enhanced green fluorescent protein(EGFP) plasmid was used as positive control and the transfection efficiency was detected by flow cytometry. Inhibitory effect of siRNAs was demonstrated by real-time quantitative RT-PCR and Western blots. Cell proliferation was measured by MTT assay and apoptosis by Annexin Ⅴ-FITC assay. Results The transfection efficiency was about 70%. The synthesized siRNAs inhibited CML bcr/abl oncogene expression at both mRNA and protein levels. siRNAs could inhibit K562 cell proliferation to 47% and 56% at 24 h and 48 h after transfection, respectively, and induce cell apoptosis from 1.00% in control group to 15.05% and 19.4% at 24 h and 48 h respectively. Conclusion At the cell level, inhibition of CML bcr/abl oncogene expression by chemically synthesized siRNAs provides the new method for anti-leukemia study.

关 键 词：RNA干扰 慢性粒细胞白血病 BCR/ABL 融合基因 抑制作用 细胞凋亡 

分 类 号：R733.72[医药卫生—肿瘤]